Compare Dyne Therapeutics Inc. Common Stock (DYN) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs MPLX LP — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while MPLX LP trades at $57.5 (market cap $57.70B). The key difference: MPLX LP is far larger — about 20.2× Dyne Therapeutics Inc. Common Stock's market cap, and MPLX LP pays a 7.57% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| DYN | MPLX | |
|---|---|---|
Market Cap | $2.86B | $57.70B |
Volume | 3,341,579 | 561,167 |
Sector | Health | Energy |
52-Week High | $26.78 | $60.51 |
52-Week Low | $14.60 | $48.53 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $2.18B | $82.80B |
Dividend Yield | — | 7.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
MPLX trades at $56.91, up 0.14% with a bearish technical signal despite strong fundamentals. The company reported $11.47B revenue and $4.91B net income for 2025, with robust profitability margins (40.45% net margin, 33.95% ROE). Recent earnings show mixed results with Q4 2025 beat but Q1 and Q2 2026 misses. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 12% upside potential.
The investment case balances strong cash flow generation and dividend yield against energy market volatility risks. MPLX's fee-based midstream model provides revenue stability, but recent technical weakness and earnings misses warrant caution. The stock offers value with a 12.24 P/E ratio and dividend income potential, though investors should monitor Q3 2026 earnings due November 3rd for confirmation of business momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
